🇺🇸 FDA
Pipeline program

Iberdomide, Iberdomide, Dexamethasone 2mg Tablets , BORTEZOMIB, DARZALEX 1800 mg solution for injection, Dexamethason-ratiopharm® 4 mg Tabletten, Iberdomide, Iberdomide

CC-220-MM-002

Phase 3 small_molecule active

Quick answer

Iberdomide, Iberdomide, Dexamethasone 2mg Tablets , BORTEZOMIB, DARZALEX 1800 mg solution for injection, Dexamethason-ratiopharm® 4 mg Tabletten, Iberdomide, Iberdomide for Relapsed or Refractory Multiple Myeloma (RRMM) is a Phase 3 program (small_molecule) at Celgene Europe Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Celgene Europe Limited
Indication
Relapsed or Refractory Multiple Myeloma (RRMM)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials